Stockscreener 앱 받기
2.715
9.50%
-0.285
시간 외 거래:
2.75
0.035
+1.29%
전일 마감가:
$3.00
열려 있는:
$2.668
하루 거래량:
141.14K
Relative Volume:
1.02
시가총액:
$964.34M
수익:
$890.87M
순이익/손실:
$-115.85M
주가수익비율:
-8.3257
EPS:
-0.3261
순현금흐름:
$-104.29M
1주 성능:
-16.20%
1개월 성능:
-2.34%
6개월 성능:
-14.35%
1년 성능:
-35.36%
1일 변동 폭
$2.632
$2.73
1주일 범위
$2.632
$3.16
52주 변동 폭
$2.308
$4.80
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
2.715 | 1.07B | 890.87M | -115.85M | -104.29M | -0.3261 |
TAK
Takeda Pharmaceutical Co Adr
|
16.64 | 51.87B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.25 | 41.70B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.02 | 40.34B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.34 | 32.26B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
579.54 | 24.69B | 3.17B | 1.29B | 1.01B | 27.09 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 재개 | H.C. Wainwright | Buy |
| 2026-02-03 | 개시 | Berenberg | Buy |
| 2025-04-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-10-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-07-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-04-04 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-11-16 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2022-01-07 | 재개 | Citigroup | Neutral |
모두보기
Evotec Se Adr 주식(EVO)의 최신 뉴스
Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth - AD HOC NEWS
Evotec places €116.1 million convertible bonds due 2033 - Investing.com UK
Evotec places €116.1 million convertible bonds due 2033 By Investing.com - Investing.com South Africa
Evotec SE stock (DE0005664809): Recent price gains signal short-term momentum - AD HOC NEWS
Evotec SE stock (DE0005664809): HC Wainwright cuts Q2 earnings outlook - AD HOC NEWS
Boyd Gaming posts downbeat Q1 results, joins Coursera, Evotec and other big stocks moving lower in Friday's pre-market session - MSN
Evotec SE stock (DE0005664809): Q1 2026 results show sharp revenue drop amid restructuring - AD HOC NEWS
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges - Investing.com Canada
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates By Investing.com - Investing.com Nigeria
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates - Investing.com
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges By Investing.com - Investing.com South Africa
Evotec reports wider quarterly loss, misses revenue expectations By Investing.com - Investing.com Canada
Evotec reports wider quarterly loss, misses revenue expectations - Investing.com
Evotec's Share Price Surges! Summer Rally for Desert Gold? Rheinmetall Shares Heading Toward EUR 2,000? - news.financial
Evotec SE Stock (DE0005664809): Q1 2026 Results Due Today - AD HOC NEWS
Evotec nominates Wolfgang Hofmann to supervisory board By Investing.com - Investing.com Australia
Evotec nominates Wolfgang Hofmann to supervisory board - Investing.com
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin By Investing.com - Investing.com Australia
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday - Benzinga
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin - Investing.com
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough for biotech recovery? - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery pipeline strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for steady ups - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for biotech re - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock biotech upside? - AD HOC NEWS
Evotec appoints Ingrid Müller as chief operating officer - Investing.com
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock new upside? - AD HOC NEWS
Evotec Q4 2025 slides: strong finish masks segment headwinds By Investing.com - Investing.com Australia
BofA reiterates Evotec stock Underperform rating on execution concerns - Investing.com
Evotec (NASDAQ: EVO) pivots to asset-light model and boosts 2025 liquidity - Stock Titan
Evotec Q4 2025 slides: strong finish masks segment headwinds - Investing.com
Earnings call transcript: Evotec SE ADR Q4 2025 sees revenue growth, stock surges - Investing.com
Evotec sees weak 2026 outlook after in-line 2025 results, $100 mln deal By Investing.com - Investing.com South Africa
Evotec sees weak 2026 outlook after in-line 2025 results, $100 mln deal - Investing.com
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal - Benzinga
Evotec Se Adr (EVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.25%
0.38%
자본화:
|
볼륨(24시간):